Amycretin: The GLP-1 + Amylin Drug Showing 25%+ Weight Loss

Every Obesity Drug So Far Has Pulled One Lever. Amycretin Pulls Two.

Semaglutide changed everything. Before Wegovy's approval in 2021, the best FDA-approved weight loss drugs produced maybe 5-10% weight loss on average. Semaglutide nearly doubled that. Then tirzepatide came along in 2023 and pushed the ceiling higher still, with some patients losing over 20% of their body weight in clinical trials. The obesity treatment revolution — one driven almost entirely by drugs that mimic a gut hormone called GLP-1 — reshaped how physicians, patients, and insurers think about weight management.

But both drugs share a limitation that becomes obvious when you look at the underlying biology: they pull on a single metabolic lever. GLP-1 receptor activation, delivered through the hypothalamus, does a lot. It suppresses appetite, slows digestion, and improves insulin sensitivity. It does not, however, address every pathway the body uses to regulate body weight. And the clinical evidence shows it: most patients on GLP-1 monotherapy hit a weight loss plateau somewhere between 15-20% of their starting weight. The body adapts. The metabolic thermostat resets. Weight loss stalls.

The question driving the next wave of obesity drug development: what happens when you stop relying on GLP-1 alone and start activating a second, independent appetite-regulation system at the same time?

Amycretin is a unimolecular GLP-1 and amylin receptor agonist developed by Novo Nordisk — a single peptide that simultaneously activates two distinct hormone pathways involved in appetite regulation and metabolic control. That word "unimolecular" matters. It means one molecule hitting two targets, not two drugs taped together in a combination pen. And the early clinical data suggests this approach produces weight loss that exceeds anything we have seen from approved medications.

In a phase 1b/2a trial published in The Lancet in June 2025, participants receiving the highest dose of subcutaneous amycretin lost 24.3% of their body weight over 36 weeks — and the weight loss curve showed no sign of plateauing. For context, semaglutide 2.4 mg (Wegovy) typically produces around 15% weight loss over 68 weeks. Amycretin got to 24% in roughly half that time.

The drug is being developed for two formulations: a once-weekly subcutaneous injection and a once-daily oral tablet. Novo Nordisk has confirmed that both formulations will advance straight to Phase 3 trials, skipping the usual Phase 2 step for the obesity indication. That decision, based on what the company describes as "feedback received from regulatory authorities," signals confidence from both the drugmaker and the FDA that the Phase 1b/2a data warrants large-scale testing.

But confidence and approval are different things entirely. The same trial that produced those headline weight loss numbers also revealed that 82% of participants experienced nausea. That figure will need to come down substantially — or be managed far more effectively — before amycretin reaches your doctor's prescription pad. Understanding why this drug produces such aggressive results, and why those results come with serious gastrointestinal tradeoffs, requires a closer look at what happens when you activate GLP-1 and amylin signaling at the same time.

Two Hormones, Two Brain Regions, One Molecule

To understand why amycretin might outperform existing drugs, you need to understand the two hormones it mimics — and why activating both simultaneously produces effects that neither achieves alone.

GLP-1: The Hormone You Already Know About

Glucagon-like peptide-1 works primarily through the hypothalamus, the brain region that functions as your metabolic thermostat. When GLP-1 receptors activate in the hypothalamus, they reduce hunger signals, slow gastric emptying (food stays in your stomach longer, so you feel full faster), and improve insulin sensitivity. This is the mechanism behind semaglutide and tirzepatide. It works. Millions of prescriptions prove it.

But GLP-1 agonists have a ceiling. At some point during treatment, most patients hit a plateau where their weight stabilizes. The body adapts. The hypothalamic circuits recalibrate. Weight loss slows, then stops — typically somewhere between 15-20% of starting body weight for the strongest approved agents.

Why does the plateau happen? Your body has evolved powerful defenses against weight loss. When you start losing fat, leptin levels drop, ghrelin rises, and the hypothalamus interprets these changes as a threat to survival. It responds by ramping up hunger signals and dialing down energy expenditure — a process researchers call metabolic adaptation. GLP-1 agonists partially override these defenses, but they work through a single signaling channel. Eventually, the compensatory mechanisms catch up. The body finds its new equilibrium, and weight loss stalls. Breaking through that plateau requires hitting the system from a different angle.

Amylin: The Overlooked Partner

Amylin is a 37-amino-acid peptide hormone that your pancreas co-secretes alongside insulin every time you eat — roughly one molecule of amylin for every 100 molecules of insulin, released from the same beta-cell secretory granules. Despite being discovered decades ago, amylin has lived in insulin's shadow. That is changing.

The hormone was first identified as "islet hyalinization" in 1900, though its true nature was not understood until 1986 when researchers isolated the peptide from pancreatic amyloid deposits. For most of the following two decades, amylin was studied primarily in the context of type 2 diabetes — where its tendency to aggregate into toxic amyloid fibrils contributes to beta-cell destruction. One amylin analog, pramlintide (brand name Symlin), was approved in 2005 as an injectable adjunct to insulin therapy for diabetes. It never became widely used. The drug required three daily injections, produced modest glucose improvements, and had an unfavorable side effect profile relative to its benefits.

What changed the calculus for amylin was the realization that its appetite-suppressing effects operate through brain circuits that are largely independent of GLP-1. This meant amylin could complement, rather than merely duplicate, the appetite suppression produced by drugs like semaglutide.

Where GLP-1 works mainly through the hypothalamus, amylin operates through a different brain structure: the area postrema in the medulla oblongata. Think of the hypothalamus as the strategic planner of appetite — it integrates long-term energy signals, hormone levels, and metabolic status to set your baseline hunger. The area postrema is more like the tactical responder. It sits outside the blood-brain barrier, directly sampling what is circulating in your blood, and fires rapid satiation signals through a relay chain: area postrema to nucleus tractus solitarius, then to the lateral parabrachial nucleus and amygdala, and finally to the lateral hypothalamus.

When amylin activates this cascade, several things happen simultaneously: appetite drops acutely, gastric emptying slows further, glucagon secretion from the pancreas is suppressed (reducing the liver's glucose output), and digestive enzyme secretion decreases. Animal studies also show that amylin enhances sensitivity to leptin — the "fullness hormone" that becomes progressively less effective in obesity — and may increase total energy expenditure.

The receptor biology adds another layer of complexity. Amylin does not have its own dedicated receptor in the traditional sense. Instead, amylin receptors are formed when a calcitonin receptor pairs with one of three receptor activity-modifying proteins (RAMPs). Each RAMP combination creates a different amylin receptor subtype — AMYR1, AMYR2, and AMYR3 — with slightly different tissue distributions and signaling properties. This explains why the amylin receptor is so sensitive to molecular modifications: the binding pocket is created by a protein complex, not a single protein, and small changes to the agonist molecule can disrupt its ability to interact with the multi-protein receptor assembly.

This receptor complexity also explains a frustrating historical problem: amylin-based drugs have been difficult to develop. Pramlintide, the only previously approved amylin analog, had a half-life of roughly 48 minutes — requiring injections before every meal. Natural human amylin's plasma half-life is even shorter, at about 13 minutes. Creating an amylin agonist that lasts long enough for once-weekly dosing, while maintaining potency across all three AMYR subtypes, was a chemical engineering challenge that took years to solve.

The Additive Logic: Two Pathways Are Better Than One

Here is the core argument for combining GLP-1 and amylin agonism: they suppress appetite through partially non-overlapping brain circuits. GLP-1 targets the hypothalamus. Amylin targets the area postrema. Both ultimately reduce food intake, but through different neuronal populations and signaling cascades. Activating both pathways simultaneously should, in theory, produce appetite suppression that exceeds what either pathway achieves alone — because the compensatory mechanisms that limit each pathway individually cannot fully compensate when both are engaged at once.

It is roughly analogous to treating high blood pressure with two drugs that work through different mechanisms (say, an ACE inhibitor and a calcium channel blocker) rather than just doubling the dose of one. The combination often works better than either drug alone, with a more favorable side effect profile per unit of efficacy, because you are hitting the problem from two directions rather than pushing harder on one.

The amylin pathway also brings something GLP-1 alone does not: direct interaction with leptin signaling. In animal studies, amylin enhanced leptin sensitivity — potentially counteracting one of the key mechanisms behind the GLP-1 weight loss plateau. If your body's ability to respond to leptin improves while GLP-1 is simultaneously suppressing appetite through the hypothalamus, the plateau may arrive later or not at all. The human data is consistent with this hypothesis (no plateau at 36 weeks), but proving the mechanism in humans will require more targeted studies.

Why One Molecule Matters More Than Two Drugs

Novo Nordisk already has a GLP-1 + amylin combination in their pipeline: CagriSema, which pairs semaglutide with cagrilintide (a long-acting amylin analog) in a dual-chamber injection pen. Two separate molecules, administered together. Amycretin takes a fundamentally different approach.

According to the preclinical characterization published in PMC, building a unimolecular dual agonist was not straightforward. When researchers tried the obvious approach — linking the amino acid sequence of cagrilintide or pramlintide (an older amylin analog) directly to semaglutide — amylin receptor potency dropped by 20 to 50-fold. The amylin receptor is apparently very sensitive to molecular modifications at its binding interface.

The solution required a different amylin backbone entirely. Amycretin uses a GLP-1 receptor agonist sequence at its N-terminus, connected via a short peptide spacer to a 32-amino-acid disulfide-free calcitonin-based amylin sequence — calcitonin being a related peptide that activates the same receptor family. An albumin-binding C18 diacid sidechain extends the molecule's half-life, which reached 29 hours in non-human primates, enough for once-weekly dosing via injection.

The design goal, per Novo Nordisk's own preclinical researchers, was a single molecule equipotent to CagriSema on both receptor systems. Whether they have achieved that in humans remains to be proven in larger trials. But the early clinical data is consistent with the hypothesis that a single molecule targeting both pathways can produce additive — or possibly synergistic — weight loss effects.

One finding from the preclinical work deserves particular attention: in diet-induced obese mice, amycretin appeared to prevent the metabolic adaptation that normally accompanies weight loss. When your body loses weight, it typically compensates by reducing total energy expenditure — your metabolism slows down to defend the higher weight. Amycretin-treated animals maintained their energy expenditure at levels higher than weight-matched control animals. The weight loss also showed favorable body composition: roughly 70% came from fat mass and 30% from lean mass. These are mouse data, not human data. But they sketch a mechanism — appetite suppression plus metabolic adaptation resistance — that lines up neatly with the clinical observation that weight loss just kept going.

24.3% at 36 Weeks — and the Curve Was Still Going Down

The phase 1b/2a trial, published in The Lancet on June 20, 2025, enrolled 125 adults at a single research center in San Antonio, Texas. Participants were 18-55 years old with a BMI of 27.0-39.9 kg/m2 and no diabetes (HbA1c below 6.5%). This was a relatively healthy overweight/obese population — not the sicker patients who might ultimately use the drug.

Of those 125 participants, 101 received amycretin and 24 received placebo. The trial ran in five parts with escalating doses:

Trial Part	Dose	Duration	Weight Loss (Amycretin)	Weight Loss (Placebo)
Part B	Up to 60 mg weekly	36 weeks	-24.3%	-1.1%
Part C	20 mg weekly	36 weeks	-22.0%	+1.9%
Part D	5 mg weekly	28 weeks	-16.2%	+2.3%
Part E	1.25 mg weekly	20 weeks	-9.7%	+2.0%

Several things stand out in this data.

The dose-response relationship is clear and steep: even the lowest dose (1.25 mg for just 20 weeks) produced nearly 10% weight loss. That low-end result, on its own, would be competitive with older anti-obesity medications at their maximum doses. The fact that it represents the floor of amycretin's dose range, not the ceiling, underscores how potent this molecule appears to be.

More striking is what happened at the top end. The 20 mg dose (Part C) produced 22.0% weight loss — only 2.3 percentage points less than the 60 mg dose. That suggests the dose-response curve may flatten between 20 mg and 60 mg, which has practical implications for Phase 3 dosing. If 20 mg achieves most of the weight loss benefit at (presumably) lower nausea rates than 60 mg, the optimal dose might end up being in that middle range rather than at the maximum tested.

The most significant finding, though, is the absence of a plateau. Weight loss curves showed no sign of plateauing at any dose level when the treatment periods ended. That 24.3% was not a final number — it was the number when they stopped the clock. Every approved obesity drug, and most in development, shows a plateau — a flattening of the weight loss curve where the body's compensatory mechanisms catch up with the drug's appetite-suppressing effects. In the STEP 1 trial, semaglutide's curve flattened around week 60. In SURMOUNT-1, tirzepatide's curve was beginning to flatten at week 72. Amycretin's curve at week 36 was still declining at roughly the same rate it had been declining since week 12.

If that trajectory continued — a big if — a year of treatment could potentially produce 30%+ weight loss. That would put amycretin in the same range as bariatric surgery outcomes, where Roux-en-Y gastric bypass typically produces 25-35% total body weight loss. No medication has reached that territory in a clinical trial.

Superiority over placebo became statistically significant by week 4 and the gap widened continuously. Exploratory metabolic markers moved in the right direction too: fasting plasma glucose fell by up to 0.8 mmol/L, and HbA1c dropped by 0.6 percentage points in the highest-dose group — notable reductions in a population that was not diabetic at baseline.

The trial demographics, reported in the American College of Cardiology's journal scan, showed the dose-response cohorts (Parts C-E) had a mean age of 37 years, 53% were women, 66% were White, 28% Black, and 51% Hispanic or Latino — reasonably representative for a single-site U.S. study.

The Oral Formulation: A Separate but Equally Striking Story

A companion phase 1 trial of once-daily oral amycretin, published simultaneously in The Lancet, randomized 144 adults with overweight or obesity to oral amycretin or placebo for up to 12 weeks. At the highest dose (two 50 mg tablets daily), participants achieved a mean weight loss of 13.1% versus 1.2% with placebo after just 12 weeks.

The oral formulation's lead author, Agnes Gasiorek, PhD, and colleagues wrote that "to date, no other oral drug has shown the same level of effectiveness in reducing body weight as observed with amycretin in individuals with overweight or obesity over a 12-week timeframe." For comparison, oral semaglutide 50 mg (the highest oral GLP-1 dose in development) achieved 15.1% weight loss — but that was over 68 weeks, nearly six times longer.

Phase 2 in Type 2 Diabetes: More Data, More Confidence

In November 2025, Novo Nordisk released Phase 2 results from 448 people with type 2 diabetes. This was a harder population to move the needle in — diabetes blunts the weight-loss response to GLP-1 drugs. Yet subcutaneous amycretin still achieved up to 14.5% weight loss versus 2.6% with placebo at 36 weeks, with HbA1c reductions of up to 1.8 percentage points. An extraordinary 89.1% of participants on the highest subcutaneous dose reached an HbA1c below 7% — the standard treatment target.

Oral amycretin in the T2D population produced up to 10.1% weight loss versus 2.5% placebo, with 77.6% achieving HbA1c below 7%. And once again, no weight loss plateau at week 36 for the higher doses. The participants on the highest subcutaneous dose had only been on their final maintenance dose for four weeks when the trial ended, suggesting the full weight loss potential had not been reached.

That four-week detail is worth pausing on. In most obesity drug trials, the dose-escalation period can last 12-20 weeks before participants reach their target dose. The weight loss observed during dose escalation reflects a submaximal drug exposure — the full effect only becomes apparent after weeks at the final dose. If amycretin's T2D participants had only been at their top dose for four weeks, the 14.5% weight loss they achieved almost certainly underrepresents what a longer exposure period would produce. This interpretation is consistent with Novo Nordisk's own characterization of amycretin as having "potential best-in-class profile" — language the company would not use lightly given the CagriSema precedent.

The T2D trial also provides reassurance on safety beyond the weight loss narrative. With 448 participants — four times the obesity trial's size — and a more medically complex patient population (many on metformin and SGLT2 inhibitors at baseline), the safety signal was consistent with what the smaller trial showed. GI side effects predominated. No unexpected serious adverse events emerged. For a drug mechanism that could theoretically interact with diabetes medications in unpredictable ways, the consistency of the safety profile across populations is encouraging.

82% Nausea: The Number That Could Make or Break This Drug

Here is the uncomfortable math: in the subcutaneous trial, 82% of participants treated with amycretin experienced nausea, 53% experienced vomiting, and 41% experienced diarrhea. Those are not small numbers. For comparison, tirzepatide Phase 3 trials (SURMOUNT-1) reported nausea in roughly 24-33% of participants depending on dose. Semaglutide 2.4 mg (STEP 1) reported nausea in about 44%. Amycretin's 82% nausea rate is in a different league.

Context helps, though it does not erase the concern.

These gastrointestinal events peaked during the up-titration phase and diminished thereafter. This is a pattern consistent with all incretin-based drugs: the GI system complains loudly when it first encounters GLP-1 and amylin agonism, then gradually adapts. The question is whether the adaptation is sufficient for real-world adherence over months and years.

Severity matters too. Novo Nordisk and the investigators classified the vast majority of these events as mild or moderate. "Mild nausea" and "severe, debilitating nausea" are different experiences, even though they both count as nausea in the adverse event tally.

The dropout rate tells a more nuanced story than the side effect percentages alone. 38 amycretin recipients (37%) discontinued the trial, compared to 4 (17%) on placebo. But here is the important detail: 59% of those discontinuations were for non-safety reasons — withdrawal of consent, recreational drug use (which disqualifies participants), or other life circumstances. The ACC's journal scan noted that only a fraction of the dropout gap between amycretin and placebo can be attributed directly to intolerability.

The Nocebo Problem

One statistical oddity deserves mention: 92% of amycretin recipients in Parts B-E reported at least one treatment-emergent adverse event — but so did 100% of placebo recipients. In a trial where everyone experiences something, the absolute percentages lose some of their shock value. The investigators attributed this in part to nocebo effects and the small sample sizes in placebo groups. When only 18 people are in a placebo arm, one or two extra adverse event reports swing the percentage dramatically.

Beyond the Gut: Dysaesthesia and Cardiac Effects

GI symptoms were not the only finding of note. Dysaesthesia — abnormal sensations like tingling or numbness — occurred in 18% of participants at the 60 mg dose and 29% at the 20 mg dose. This is a less common side effect with GLP-1 monoagonists and may be related to amylin's neurological activity. It warrants monitoring in larger trials.

On the cardiac front, continuous electrocardiography showed no clinically relevant QT prolongation. A transient increase in pulse rate of approximately 10 beats per minute after initial injections resolved on its own — a pattern seen with other GLP-1 agonists.

The Lancet study authors themselves flagged an important caution: "The rapid loss of body weight seen in such clinical trials might not result in the beneficial effects observed following a more gradual reduction, and further research is required to better understand the optimal rate to improve overall health." Rapid weight loss can accelerate lean muscle loss, trigger gallstones, and create nutritional deficiencies. The speed of amycretin's effects may itself prove to be a challenge that requires careful dose titration protocols in Phase 3.

Why Is the Nausea Rate So High?

Both GLP-1 and amylin receptors influence the chemoreceptor trigger zone — the part of the brainstem that detects potential toxins in the blood and triggers the vomiting reflex. When you activate GLP-1 receptors alone, you get a dose-dependent nausea response. When you add amylin receptor activation on top — particularly through the area postrema, which sits right next to the chemoreceptor trigger zone — you get compounded nausea signaling.

This is the unavoidable tradeoff of dual agonism: the same brain region that mediates amylin's powerful satiation effects also mediates its nausea-inducing effects. The area postrema does not distinguish between "you are full, stop eating" and "something is wrong, prepare to vomit." Both signals travel through overlapping pathways. The more aggressively you activate those pathways, the more weight loss you get — but also the more GI distress.

The dose-titration approach addresses this partially. By starting at low doses and escalating gradually, the GI system adapts to the dual agonism over weeks. The phase 1b/2a trial used dose escalation in all cohorts, and the investigators noted that GI events diminished after the escalation period. But the 82% aggregate number includes the escalation period, which inflates the lifetime incidence. What matters more for real-world use is the steady-state tolerability — how many patients experience ongoing, persistent nausea versus transient nausea during dose increases. Those data were not broken out in the published results, and Phase 3 trials will need to provide them.

Comparing Nausea Rates Across Drugs

Drug	Nausea Rate	Vomiting Rate	Trial Phase
Amycretin (SC)	82%	53%	Phase 1b/2a
Semaglutide 2.4mg	~44%	~25%	Phase 3 (STEP 1)
Tirzepatide 15mg	~33%	~12%	Phase 3 (SURMOUNT-1)
Tirzepatide 10mg	~24%	~9%	Phase 3 (SURMOUNT-1)
CagriSema	~47%	~22%	Phase 3 (REDEFINE 1)

A critical nuance: earlier-phase trials almost always report higher adverse event rates than Phase 3 trials. Phase 1 and 2 studies use smaller sample sizes, often faster dose escalation, and enroll participants in controlled research settings where every symptom is meticulously documented. When drugs move to Phase 3 with thousands of participants in real-world clinical settings, nausea rates typically moderate. Semaglutide's nausea rate was higher in early studies than the 44% reported in STEP 1. The same may prove true for amycretin — but by how much remains uncertain.

GI Side Effect Summary — Amycretin Phase 1b/2a (SC): Nausea 82% | Vomiting 53% | Diarrhea 41% | Events peaked during up-titration, diminished over time | Vast majority mild/moderate severity | 37% total discontinuation rate (59% for non-safety reasons)

How Amycretin Stacks Up Against the Competition

Cross-trial comparisons in obesity medicine are inherently imperfect. Different trials use different patient populations, different endpoints, different durations, and different dosing protocols. A comprehensive PMC pipeline review cataloging every anti-obesity medication in clinical development provides the best available framework for comparison, even with those caveats.

Drug	Mechanism	Phase	Duration	Weight Loss	Route
Amycretin	GLP-1 + Amylin	Phase 2	36 weeks	24.3%	SC weekly
Amycretin	GLP-1 + Amylin	Phase 1	12 weeks	13.1%	Oral daily
Retatrutide	GLP-1 + GIP + Glucagon	Phase 2	48 weeks	24.2%	SC weekly
CagriSema	GLP-1 + Amylin (two drugs)	Phase 3	68 weeks	22.7%	SC weekly
Tirzepatide	GLP-1 + GIP	Approved	72 weeks	~22.5%	SC weekly
Survodutide	GLP-1 + Glucagon	Phase 2	46 weeks	18.7%	SC weekly
Semaglutide 2.4mg	GLP-1	Approved	68 weeks	~15%	SC weekly
Oral Semaglutide 50mg	GLP-1	Phase 3	68 weeks	15.1%	Oral daily
Orforglipron	GLP-1	Phase 2	36 weeks	14.7%	Oral daily
MariTide	GLP-1 + GIP antagonist	Phase 2	52 weeks	20%	SC monthly

The comparison with retatrutide — Eli Lilly's triple agonist targeting GLP-1, GIP, and glucagon receptors — is the most instructive. Both drugs produced nearly identical peak weight loss (24.3% vs. 24.2%), but amycretin got there in 36 weeks versus retatrutide's 48 weeks. Whether that faster trajectory reflects genuine superiority or just different dose-escalation schedules is impossible to determine without a head-to-head trial. If you want to learn more about the triple agonist approach, we have covered retatrutide's mechanism and trial data in detail.

The comparison with CagriSema — Novo Nordisk's other GLP-1/amylin combination — is more troubling for that drug than it is flattering for amycretin. CagriSema reached 22.7% weight loss, but required 68 weeks to get there. Amycretin exceeded that number in half the time. And CagriSema has had a rocky Phase 3: the REDEFINE 1 results disappointed investors, missing some expectations despite technically meeting its primary endpoint. Cantor Fitzgerald analyst Prakhar Agrawal noted that amycretin's amylin-targeting component appears more potent than what CagriSema achieves with its two-drug approach.

What the Numbers Do Not Tell You

Raw weight loss percentages, stripped of context, are misleading. Several factors make the comparison between amycretin and everything else harder than it looks on a table.

Trial duration matters enormously. Amycretin's 24.3% was achieved in 36 weeks with no plateau. Retatrutide's 24.2% was measured at 48 weeks — also without a clear plateau. If both drugs had been tested for, say, 72 weeks (the duration of the SURMOUNT-1 tirzepatide trial), both might have reached 30% or higher. We do not know. The apparent tie at ~24% may reflect nothing more than the fact that both trials stopped at different points on still-descending curves.

Patient population skews the results too. Amycretin's Phase 1b/2a enrolled relatively young (18-55), non-diabetic participants with a BMI ceiling of 39.9. The STEP 1 semaglutide trial enrolled participants up to BMI 60 with more comorbidities. Heavier, sicker populations tend to lose a lower percentage of body weight on the same drug, partly because their metabolic dysfunction is more entrenched. Amycretin's numbers may look less exceptional in Phase 3 with a broader patient population.

Single-site trials are also inherently less noisy than multi-site trials. When every participant is evaluated by the same team at the same facility (as in the amycretin Phase 1b/2a), variability decreases and treatment effects can appear larger. Phase 3 trials across dozens of sites and countries typically show some efficacy attenuation compared to tightly controlled early trials.

None of this means amycretin's results are inflated or unreliable. It means the comparison should come with a margin of error. A fair summary: amycretin appears to produce weight loss at least as potent as any drug currently in development, with the strongest evidence for speed of onset. Whether the final Phase 3 numbers land at 20%, 24%, or somewhere in between will depend on the trial population, the dose-titration protocol, and how long the trials run.

The Oral Formulation Changes the Game

Perhaps amycretin's most strategically significant advantage is its oral form. The obesity drug market is currently dominated by injectables, and that matters more than pharma executives might like to admit. Patient surveys consistently show that a significant fraction of people eligible for GLP-1 therapy either delay treatment or decline it entirely because of needle aversion. Self-injection is a barrier — psychological, practical, and sometimes physical. An oral formulation removes that barrier completely.

The numbers favor oral amycretin in the oral drug category. Many patients — and their doctors — prefer pills. Eli Lilly's orforglipron (an oral GLP-1 agonist) managed 14.7% weight loss over 36 weeks. Oral amycretin achieved 13.1% in just 12 weeks with no plateau in sight. Oral semaglutide 50 mg reached 15.1%, but over 68 weeks. If oral amycretin's trajectory continues in longer trials, it could surpass everything in the oral category by a wide margin.

As Bernard Khoo, PhD, and Tricia M-M Tan, PhD, wrote in their Lancet editorial accompanying the studies: "Head-to-head outcome studies comparing GLP-1 receptor monoagonists with GLP-1 plus amylin receptor multiagonists are required to definitively establish their added value and, hence, their place in obesity management." Until those head-to-head studies exist, all comparisons across trials come with significant uncertainty. For a broader understanding of how GLP-1 drugs work and their safety profiles, see our GLP-1 weight loss drugs safety guide.

From Lab to Pharmacy: What the Phase 3 Timeline Actually Looks Like

Novo Nordisk has stated that Phase 3 clinical trials for amycretin could begin in early 2026, testing both the injectable and oral formulations. A separate Phase 3 program for type 2 diabetes is also planned for 2026. Martin Holst Lange, Novo Nordisk's chief scientific officer, described the plans as "an extensive phase 3 development programme across multiple indications."

What does "extensive" mean in practice? Based on standard FDA requirements for obesity drugs and the typical Phase 3 timeline for this class:

Milestone	Estimated Timeline	What Happens
Phase 3 trial initiation	Early-mid 2026	Multiple large trials begin enrolling, likely 1,000-3,000+ participants each
Phase 3 primary results	2028-2029	12-18 months of treatment + data analysis; Novo may seek fast-track or breakthrough therapy designation
Regulatory submission	2029-2030	NDA or BLA filed with FDA, MAA with EMA
Approval decision	2030-2031	Standard review ~12 months; priority review ~6 months if granted

A few factors could accelerate or delay this timeline. On the accelerating side: the FDA has shown willingness to move quickly on obesity drugs, and Novo Nordisk's statement that they received "feedback from regulatory authorities" supporting the jump from Phase 1b/2a directly to Phase 3 suggests the agency may be open to expedited pathways. The company has also been granted both subcutaneous and oral formulations advancing simultaneously, which means parallel development rather than sequential.

On the delaying side: the 82% nausea rate may require Novo Nordisk to test slower dose-titration schedules, which extends trial duration. The FDA will almost certainly require cardiovascular outcome data, or at minimum, a commitment to post-marketing cardiovascular studies. Prof Naveed Sattar of the University of Glasgow, commenting on the early data, stated directly: "far larger scale trials will be needed to test such medicines in due course, including its effect on disease outcomes."

The Regulatory Landscape for Obesity Drugs

The FDA's attitude toward obesity drugs has shifted meaningfully since 2021. The agency approved semaglutide 2.4 mg in June 2021, tirzepatide for obesity in November 2023, and has since expanded approved indications for these drugs to include cardiovascular risk reduction and related conditions. The agency appears receptive to drugs that demonstrate large, clinically meaningful weight loss, even when GI side effects are substantial — as long as the benefit-risk ratio is favorable.

For amycretin specifically, the FDA's reported willingness to let Novo Nordisk skip directly from Phase 1b/2a to Phase 3 (bypassing a formal Phase 2 in obesity) is an encouraging signal. Regulatory agencies typically only endorse this accelerated path when early data is strong enough to justify the risk of a larger investment. It does not guarantee approval, but it does suggest the FDA sees the mechanism and the data as promising enough to warrant expedited evaluation.

The European Medicines Agency (EMA) operates on a similar but distinct timeline. EMA approvals for obesity drugs have generally lagged the FDA by 6-18 months. If amycretin reaches FDA submission by 2029-2030, European availability would likely follow by 2031 at the earliest.

Cost and reimbursement present a separate challenge. Current GLP-1 agonists cost roughly $1,000-1,300 per month in the United States without insurance. Insurance coverage remains inconsistent — many plans exclude weight loss medications entirely, and Medicare does not cover them (though legislation to change this has been proposed multiple times). Amycretin's pricing is unknown, but if Novo Nordisk positions it as a premium next-generation therapy, access could be limited to patients with generous pharmacy benefits. The oral formulation may offer a manufacturing cost advantage over injectables, potentially translating to lower pricing — but pharmaceutical pricing decisions rarely follow manufacturing costs.

The broader context matters here. Novo Nordisk is under significant competitive and financial pressure. The company's share price fell more than 40% over the past year as Eli Lilly's Zepbound eroded Wegovy's market share and CagriSema's Phase 3 results disappointed. Former CEO Lars Fruergaard Jorgensen stepped down. Amycretin represents a critical opportunity for Novo Nordisk to regain momentum — which creates both motivation to move fast and pressure to get it right.

The Amylin Gold Rush Has Started

Amycretin did not create interest in amylin-targeting drugs. But it has turbocharged it. The pharmaceutical industry's conviction that amylin is a valuable therapeutic target can be measured in dollars.

Roche paid more than $1 billion to acquire petrelintide, an amylin analog developed by Zealand Pharma that showed 8.3% weight loss as a standalone agent in Phase 1. AbbVie signed a deal worth close to $2 billion with Denmark-based Gubra for GUBamy, another amylin-targeting molecule. Eli Lilly has its own amylin-targeting medicine in Phase 2 development. Metsera, a smaller biotech, saw its share price jump by double digits after reporting Phase 1 data for yet another amylin agent.

This wave of investment reflects a shift in how the industry thinks about weight loss pharmacology. The GLP-1 receptor is no longer the only game worth playing. As Dr. Nerys Astbury, Associate Professor of Diet and Obesity at the University of Oxford, noted in her independent commentary on the amycretin data: "Having a greater range of safe and effective prescription medications opens up the pharmaceutical treatment options for people living with obesity." She also pointed out that increased competition among drugmakers will "likely bring down the costs of these classes of medications in the longer-term" — a significant consideration given the current $1,000+/month pricing of GLP-1 agonists.

But the enthusiasm should be tempered by what remains unknown. The Lancet editorial by Khoo and Tan captured this tension precisely: "Although additional weight loss is welcome and helpful, our evolving concept of obesity management has now shifted towards an emphasis on the reduction of the risks and burdens of cardiovascular disease and other comorbidities."

Semaglutide has proven cardiovascular benefits (the SELECT trial showed a 20% reduction in major cardiovascular events). Tirzepatide's cardiovascular data is building. For amycretin, cardiovascular outcome data does not exist yet — and it will not exist for years. No matter how impressive the weight loss numbers, regulators, payers, and clinicians will need to see that amycretin actually reduces heart attacks, strokes, and cardiovascular deaths before it can claim to be a complete obesity treatment.

The Bigger Picture: Multi-Agonism as a Paradigm

Step back from amycretin specifically, and a pattern emerges. The most effective obesity drugs in development — retatrutide, amycretin, CagriSema, survodutide — all target multiple hormone receptors. The era of single-target drugs producing 10-15% weight loss appears to be giving way to a multi-agonist era producing 20-25%+.

The implications go beyond weight loss percentages. If these drugs can sustainably produce 20%+ weight loss without intolerable side effects, they may functionally eliminate the need for bariatric surgery for many patients. They may reduce type 2 diabetes incidence to the point where the disease becomes rare in treated populations. They may transform cardiovascular risk profiles on a population scale.

But they may also create new problems. Rapid, drug-induced weight loss at this magnitude raises questions about muscle mass preservation, bone density effects, nutritional adequacy, and psychological adaptation. The body was not designed to lose a quarter of its mass over nine months. Even if the metabolic markers improve, the musculoskeletal and nutritional consequences of that rate of change need to be studied carefully.

Amylin specifically brings an additional consideration. The area postrema, where amylin exerts its primary appetite effects, also plays a role in the body's response to chemotherapy-induced nausea, motion sickness, and other conditions involving emetic pathways. Long-term activation of area postrema neurons through amylin agonism is uncharted territory. It may be completely fine. It may produce tolerance that reduces efficacy over time. It may have effects on other area postrema functions that have not been investigated. Phase 3 trials of 12-18 months' duration will begin to answer these questions, but definitive long-term safety data will require post-marketing surveillance over years.

What Should Patients Take Away?

If you are currently using or considering a GLP-1 agonist for weight management, amycretin does not change your immediate options. It is an investigational drug that will not be on pharmacy shelves before 2030 at the absolute earliest. Semaglutide, tirzepatide, and their variants remain the standard of care, and they remain excellent options. The weight loss and metabolic improvements they produce are well-documented across multiple large Phase 3 trials and years of real-world clinical experience.

Do not make treatment decisions based on pipeline drugs. If your physician recommends starting or continuing a GLP-1 agonist, the existence of amycretin in clinical development is not a reason to wait. The drug that exists and works today is always better than the drug that might exist and might work better in five years.

What amycretin does signal is that the ceiling for pharmacological weight loss has not been reached. The 15-20% weight loss range that defined the GLP-1 era may prove to be a stepping stone rather than a destination. Dual and triple agonists targeting different combinations of metabolic hormones — GLP-1 plus amylin, GLP-1 plus GIP, GLP-1 plus GIP plus glucagon — are all producing weight loss numbers in the 20-25% range in early trials. Whether those numbers hold up in larger, longer studies with diverse populations remains the central question.

The nausea question looms large. A drug that makes 82% of users nauseated, even temporarily, faces real-world adherence challenges that no amount of efficacy data can overcome. Novo Nordisk will need to demonstrate — in thousands of patients over a year or more — that improved dose-titration protocols can bring GI side effects closer to the rates seen with existing drugs.

If they can, amycretin has the potential to redefine what weight loss medication achieves. A pill or injection that produces bariatric-surgery-level results without surgery, without anesthesia, without permanent anatomical changes — that is a qualitatively different proposition than anything on the market today. It would reshape how obesity is treated, how insurers calculate cost-effectiveness, and how patients and clinicians think about the risk-benefit calculus of pharmacological versus surgical intervention.

If they cannot manage the nausea, amycretin may still contribute to the field as a proof of concept. It demonstrates, definitively, that dual GLP-1/amylin agonism produces greater weight loss than GLP-1 alone. That biological insight will inform the design of future drugs even if amycretin itself never reaches the market in its current form. Other companies — and Novo Nordisk itself — may find ways to capture the same efficacy with better tolerability through different molecular designs, different dosing strategies, or different formulation approaches.

Either way, the data from this Phase 1b/2a trial has already shifted the goalposts. The obesity drug field is no longer asking "can we get to 15% weight loss?" That question was answered by semaglutide. It is now asking "can we get to 25% or 30% — and can patients tolerate the ride?" Amycretin suggests the answer to the first question is yes. The answer to the second remains unanswered until larger, longer trials report tolerability and discontinuation data.

What We Still Do Not Know

For all the excitement around amycretin's early results, the gaps in the evidence base are substantial. Listing them honestly is not pessimism — it is the kind of sober assessment that separates useful health information from hype.

Long-term efficacy beyond 36 weeks. We have no human data on what happens after 36 weeks of amycretin treatment. Does the weight loss curve continue downward? Does it eventually plateau? Does weight regain begin if the drug is stopped (as it does with semaglutide and tirzepatide)? Phase 3 trials will run for 52-68+ weeks and begin to answer these questions, but definitive long-term data will take years to accumulate.

Body composition in humans. The preclinical data showed 70% fat loss and 30% lean mass loss. In humans, this ratio is unknown. Rapid weight loss from any cause tends to produce greater lean mass loss than slower weight loss. The speed of amycretin's effects raises legitimate concerns about whether patients are preserving enough muscle mass — which matters enormously for metabolic health, functional capacity, and weight maintenance after treatment ends.

Weight regain after discontinuation. Every GLP-1 agonist studied to date shows substantial weight regain after the drug is stopped. The STEP 1 extension trial showed that most semaglutide-related weight loss returned within a year of discontinuation. There is no reason to assume amycretin will be different. If the drug works through appetite suppression rather than permanent metabolic reprogramming, the appetite comes back when the drug stops. This means amycretin, if approved, would likely need to be taken indefinitely — raising cost and adherence questions.

Cardiovascular outcomes. No cardiovascular outcome data exists. Given that cardiovascular disease is the leading cause of death in people with obesity, and given that semaglutide has demonstrated a 20% reduction in major adverse cardiovascular events (the SELECT trial), any competing obesity drug will be judged partly on its cardiovascular safety and efficacy. Amycretin may prove to have similar or even superior cardiovascular benefits — the weight loss magnitude would suggest so — but this is speculation until trials are conducted.

Cancer screening effects. GLP-1 agonists carry a boxed warning about thyroid C-cell tumors based on rodent data. Amycretin's calcitonin-based amylin component adds a wrinkle, since calcitonin itself is produced by thyroid C-cells. Whether amycretin's calcitonin-derived backbone has any effect on C-cell biology in humans has not been specifically addressed in the published literature.

Interactions with other medications. The Phase 2 T2D trial provided preliminary data on co-administration with metformin and SGLT2 inhibitors. But real-world patients often take multiple medications — statins, antihypertensives, antidepressants, oral contraceptives — and the drug interaction profile of amycretin has not been fully characterized. The slowing of gastric emptying by both GLP-1 and amylin pathways could theoretically affect absorption kinetics of co-administered oral medications.

Frequently Asked Questions

What makes amycretin different from Ozempic or Wegovy?

Ozempic and Wegovy contain semaglutide, which activates only GLP-1 receptors. Amycretin is a single molecule that activates both GLP-1 and amylin receptors simultaneously. Amylin is a separate appetite-regulating hormone that works through different brain circuits (the area postrema rather than just the hypothalamus). This dual mechanism produced 24.3% weight loss in 36 weeks in early trials — substantially more than semaglutide's typical 15% over 68 weeks. However, amycretin is still investigational and years from potential FDA approval.

When will amycretin be available to patients?

Novo Nordisk plans to begin Phase 3 trials in early 2026. If those trials succeed, regulatory submissions would likely occur around 2029-2030, with potential approval in 2030-2031. Both injectable and oral formulations are being developed simultaneously, which could mean either form reaches the market first depending on trial results and regulatory decisions.

Is the 82% nausea rate a serious concern?

It is a significant finding that needs resolution before approval. In the Phase 1b/2a trial, nausea peaked during the dose-escalation period and diminished over time, and the vast majority of events were classified as mild or moderate. Novo Nordisk will likely test slower dose-escalation schedules in Phase 3 to reduce GI side effects. For context, all GLP-1 agonists cause nausea — semaglutide at about 44%, tirzepatide at 24-33% — so the question is whether amycretin's rate can be brought closer to those ranges through optimized dosing.

How does amycretin compare to retatrutide?

Both drugs produced similar peak weight loss: amycretin at 24.3% (36 weeks) versus retatrutide at 24.2% (48 weeks). They work through different dual mechanisms — amycretin targets GLP-1 plus amylin, while retatrutide targets GLP-1 plus GIP plus glucagon. Both are in early development stages and neither can be considered superior until head-to-head trials are conducted. Retatrutide is being developed by Eli Lilly and is also entering Phase 3.

Will amycretin be available as a pill?

Yes, Novo Nordisk is developing both an oral tablet (once-daily) and a subcutaneous injection (once-weekly). The oral form showed 13.1% weight loss in just 12 weeks in its Phase 1 trial. Both formulations will enter Phase 3 development, so both could potentially reach the market — though the injectable version, with its stronger efficacy data so far, may arrive first.